Sofinnova Partners related stories
All articles and analysis
Side Letter: PE's $160trn grailPrivate equity's biggest hitters take aim at the $160 trillion retail market, according to panellists at IPEM Paris. Plus: PE and VC deal values hit a four-year low; and Australian private investments are outperforming publicly traded instruments. Here's today's brief, for our valued subscribers only.
GPs in crisis: Narrow your focusMarket downturns often widen the divide between winners and losers. Fund managers that find a specialisation are likely to gain an edge.
GP consolidation to deepen in difficult fundraising environment – IPEM panelThe high cost of operations, capital constraints and an attraction to specialists are all factors driving M&A activity among PE firms.
Bpifrance turns innovation into growthThe sovereign investor, which ranked 13th in this year’s list, is well known for encouraging its GPs to innovate sustainably and expand into new areas of investment.
The Nordic 'thought leader' LP that's sceptical of GPs going publicSwedish insurer Skandia Asset Management doesn't just go with the flow. Its head of private equity and infrastructure, Daniel Winther, discusses his bearish outlook on of continuation funds, sponsors listing and ESG targets.
CHART: The biggest dedicated life sciences capital raisersDedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
Side Letter: Advent's timely $26bn; Cathay's €500m health kick; UK's climate crackdownAdvent International's gargantuan fundraise should be well placed to capitalise on new take-private opportunities. Plus: Cathay Capital has joined the life sciences party and the UK is getting demanding when it comes to climate disclosures. Here's today's brief, for our valued subscribers only.
Side Letter: Horizon's Ukraine learnings; Apollo's €1bn life sciences buy; Onex fundraising warningHorizon Capital's Lenna Koszarny discusses the Ukrainian firm's efforts to safeguard staff and portco employees in the wake of Russia's invasion. Plus: Apollo has become the latest firm to snap up a life sciences unit and Onex warns fundraising could take longer than usual. Here's today's brief, for our valued subscribers only.
Klarna investment helps lift Skandia’s PE portfolio to all-time highPrivate equity recorded its best performance last year for the €60bn Swedish insurer ahead of a year when returns will be ‘challenging’ to replicate, its senior portfolio manager tells PEI.
Sofinnova Partners Raises €472mSofinnova Capital X has held a final close.